Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) has surged over 15%, with a cumulative increase of over 40% in the month, driven by significant news regarding its breast cancer candidate drug LAE002 [1] Company Summary - Lai Kai Pharmaceutical's stock price reached 16.95 HKD, with a trading volume of 58.22 million HKD as of the report [1] - On November 12, Lai Kai Pharmaceutical granted the rights for LAE002 in China to Qilu Pharmaceutical, with a total transaction amount of 2.045 billion RMB [1] - The company is entitled to receive a tiered sales commission ranging from 10% to over 20% [1] Industry Summary - The domestic sales peak for LAE002 is estimated to be around 2 billion RMB, while global sales peak can be referenced from Capivasertib [1] - Capivasertib is projected to have sales expectations of 700-800 million USD this year, with a sales peak estimated between 1-2 billion USD [1]
港股异动 | 来凯医药-B(02105)再涨超15% 月内累涨超四成 LAE002近期斩获BD大单